Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Remedium bio

Explore full profile

Remedium Bio is a Boston based gene therapy company focused on the development of highly innovative treatments for a broad range of diseases.

Needham, United StatesFounded 2020Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2026
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Remedium bio and the history behind them.

About Remedium bio

Remedium Bio is a biotechnology startup based in Needham, Massachusetts, focused on developing innovative gene therapies to cure chronic and life-threatening diseases. The company operates in the healthcare and biotechnology market, targeting conditions such as Type 1 and Type 2 Diabetes, myocardial infarction (heart attacks), and circulating enzyme deficiencies. These diseases are significant health challenges globally, affecting millions of people and often leading to severe complications or death.

Read full description

Remedium Bio's business model revolves around leveraging proven therapeutic targets, commercial delivery vectors (methods to deliver treatments to patients), and established manufacturing technologies to create effective gene therapies. Gene therapy involves altering the genes inside a person's cells to treat or stop disease. This approach is particularly promising for conditions that currently have limited treatment options, such as lifelong insulin replacement for diabetes or high mortality rates following heart attacks.

The company primarily serves patients suffering from chronic and severe diseases, healthcare providers, and potentially pharmaceutical companies looking for advanced treatment options. By focusing on gene therapy, Remedium Bio aims to provide long-term solutions rather than just managing symptoms, which is a significant shift from traditional treatments.

Remedium Bio generates revenue through the development and commercialization of its gene therapy products. This includes licensing its technology to pharmaceutical companies, partnering with healthcare providers for clinical trials, and eventually selling its therapies once they receive regulatory approval.

In summary, Remedium Bio is a pioneering biotech firm dedicated to curing chronic diseases through advanced gene therapy techniques, targeting a market with high unmet medical needs and significant potential for growth.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
Needham, United States
Employees
19
Open positions
None listed
Dealroom signal
82.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Gene Therapy, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Latest news

Press, funding announcements and product moves mentioning Remedium bio.

See all news

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AEquity / VC Aug 2026 $10M $40M Eli Lilly · LifeSpan Vision Ventures
EARLY VCEquity / VC Sep 2024 $0 LifeSpan Vision Ventures
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Remedium bio website traffic

Latest recorded traffic for Remedium bio is 1.5K monthly website visits, down 40% over the last three months. Remedium bio's team grew 18.8% over the past year.

Latest monthly visits1.5K 3-month web change-40% 1-year team growth+18.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed8 investors entered at this stage

  • LongevityTech.fund
  • Sherwood Ventures
  • MicroVentures
  • Primo Medical Group
  • Guindy Alumni Angels
  • Angel Star Ventures
  • Apis Health Angels
  • US National Science Foundation

Series A2 investors entered at this stage

  • LifeSpan Vision Ventures
  • Eli Lilly

Other known investors4 additional known investors

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Remedium bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Remedium bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.